Section edited by Karoly Szuhai
This section covers cytogenetics, molecular genetics and new technological advances. We encourage submission of studies on alterations at the chromosomal and DNA levels in disease prognosis.
Section edited by Karoly Szuhai
This section covers cytogenetics, molecular genetics and new technological advances. We encourage submission of studies on alterations at the chromosomal and DNA levels in disease prognosis.
EGFR and HER2 overexpression has been reported to play important roles in colorectal cancer (CRC) development and metastasis. Ovarian metastasis is rare yet is one of the most malignant metastases of CRC, but ...
Citation: BMC Clinical Pathology 2019 19:3
The overexpression of HER2 is associated with worse prognosis of breast cancer which responds favourably to anti-HER2 therapy. The objective of this study was to determine the frequency of HER2 and its associa...
Citation: BMC Clinical Pathology 2019 19:1
Advanced gastric cancers are usually associated with incurable conditions for which systemic treatments are indicated. Recent studies suggest that circulating cell-free plasma DNA of tumour origin (tDNA) is a ...
Citation: BMC Clinical Pathology 2018 18:12
The growth of tumor cells is accompanied by mutations in nuclear and mitochondrial genomes creating marked genetic heterogeneity. Tumors also contain non-tumor cells of various origins. An observed somatic mit...
Citation: BMC Clinical Pathology 2017 17:6
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PIK3CA, is one of the most frequently mutated genes in breast cancer, and the mutation status of PIK3CA has clinical relevance related to r...
Citation: BMC Clinical Pathology 2015 15:20
Germline mutations in BRCA1 or BRCA2 lead to a high lifetime probability of developing ovarian or breast cancer. These genes can also be involved in the development of non-hereditary tumours as somatic BRCA1/2 pa...
Citation: BMC Clinical Pathology 2015 15:5